IN VIVO’s Deals Of The Month: April 2016
IN VIVO’s editors pick April's most significant deals, including DalCor Pharma's big B round and a rash of NASH deals. (Article free with registration.)
You may also be interested in...
Regeneron stayed busy during the past two weeks, collaborating and making an equity commitment to CRISPR gene-editing biotech Intellia and signing an immuno-oncology deal with MedImmune. Allergan bounced off the termination of its merger with Pfizer by partnering with Heptares in neurological disease.
California biotech acquires rights to Suganon, approved for type 2 diabetes in South Korea, while partner Dong-A gets domestic rights to NASH candidate cenicriviroc.
CEO Brent Saunders says company now is "recharged" and "ready to go," and it ends the day announcing a partnership wth Heptares.